Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC

BACKGROUND: Despite the fact that numerous clinical and preclinical studies have demonstrated the synergistic effects of combining antiangiogenic or chemotherapy with immunotherapy, no data have been found to indicate that combination therapy is more effective and safer as second-line therapy. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hongxiang, Zhong, Peiyuan, Zhu, Xie, Fu, Silv, Li, Siling, Peng, Sujuan, Liu, Yangyang, Lu, Zhihui, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076840/
https://www.ncbi.nlm.nih.gov/pubmed/37035161
http://dx.doi.org/10.3389/fonc.2023.1137224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076840/
https://www.ncbi.nlm.nih.gov/pubmed/37035161
http://dx.doi.org/10.3389/fonc.2023.1137224

Ejemplares similares